Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sumitomo Awards AlphaNavi Worldwide Rights to Neuropathic Pain Therapy
October 27, 2023
- Takeda’s H1 Profit Tumbles on Write-Down Tied to Trial Setbacks, Outlook Slashed
October 27, 2023
- Merck Sues Sawai over Januvia Generics Approved in Japan
October 27, 2023
- Novartis Expects Limited Impact of siRNA Therapy in Drug Cost: Exec
October 26, 2023
- Yoshindo Recalls Some Nizatidine Products over Carcinogen Risks
October 26, 2023
- Japan Approves Spikevax for Primary Shots in Six Months and Above
October 26, 2023
- BMS Files Repotrectinib in Japan for ROS1-Positive NSCLC
October 26, 2023
- With Wholesalers Narrowed Down, Hospitals Face Squeezed Discounts for GSK Products
October 25, 2023
- Yakult to Divest Cancer Portfolio to Takata, Pull Plug on New Development
October 25, 2023
- Roche Group, Biogen Reach Settlement over Actemra Biosimilar
October 25, 2023
- Tecentriq Plus Avastin, Chemo Hit Goal in Extensive-Stage SCLC
October 25, 2023
- Ono, Turbine Ink Research Collab in Hunt for Oncology Targets
October 25, 2023
- Prostate Cancer Med Orgovyx Approved in Canada: Sumitomo
October 25, 2023
- Sawai Fudged Quality Tests of Gastritis Drug for 8 Years, Awaiting Penalty Decision
October 24, 2023
- Janssen Files PAH Fixed-Dose Combo Drug in Japan
October 24, 2023
- Enhertu Gets EU Nod for NSCLC, Triggers US$75 Million Milestone
October 24, 2023
- Pfizer Japan Recalling Docetaxel IV Infusion 20 mg/2 mL
October 23, 2023
- Daiichi Sankyo, Merck in Global ADC Deal Worth Up to US$22 Billion
October 23, 2023
- Myfembree Gets Canada Nod for Uterine Fibroid, Endometriosis
October 23, 2023
- Takeda’s Adcetris Approved in Europe for 7th Indication
October 23, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…